NASDAQ:COLLCollegium Pharmaceutical Stock Price, Forecast & News

Collegium Pharmaceutical's stock was trading at $17.57 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, COLL shares have decreased by 6.0% and is now trading at $16.52. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Collegium Pharmaceutical.

Collegium Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Collegium Pharmaceutical.

Collegium Pharmaceutical Inc (NASDAQ:COLL) released its quarterly earnings data on Thursday, May, 7th. The specialty pharmaceutical company reported $0.01 EPS for the quarter, missing the Zacks' consensus estimate of $0.66 by $0.65. The specialty pharmaceutical company had revenue of $76.51 million for the quarter, compared to analysts' expectations of $76.64 million. Collegium Pharmaceutical had a negative return on equity of 12.62% and a negative net margin of 4.21%. The firm's revenue was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.29) EPS. View Collegium Pharmaceutical's earnings history.

Collegium Pharmaceutical updated its FY 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $300-320 million, compared to the consensus revenue estimate of $318.44 million.

8 analysts have issued twelve-month price objectives for Collegium Pharmaceutical's stock. Their forecasts range from $22.00 to $43.00. On average, they anticipate Collegium Pharmaceutical's share price to reach $32.50 in the next twelve months. This suggests a possible upside of 96.7% from the stock's current price. View analysts' price targets for Collegium Pharmaceutical.

News articles about COLL stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Collegium Pharmaceutical earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Collegium Pharmaceutical.

Collegium Pharmaceutical saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 5,020,000 shares, an increase of 13.3% from the June 15th total of 4,430,000 shares. Based on an average trading volume of 457,800 shares, the days-to-cover ratio is currently 11.0 days. Currently, 15.8% of the shares of the company are sold short. View Collegium Pharmaceutical's Current Options Chain.

Some companies that are related to Collegium Pharmaceutical include SAGE Therapeutics (SAGE), Turning Point Therapeutics (TPTX), IGM Biosciences (IGMS), Principia Biopharma (PRNB), Uniqure (QURE), Ligand Pharmaceuticals (LGND), Eidos Therapeutics (EIDX), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), Xencor (XNCR), Corcept Therapeutics (CORT), I-Mab (IMAB), Aurinia Pharmaceuticals (AUPH), Myovant Sciences (MYOV) and Intra-Cellular Therapies (ITCI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), AbbVie (ABBV), NVIDIA (NVDA), Canopy Growth (CGC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Bausch Health Companies (BHC), Intercept Pharmaceuticals (ICPT), Advanced Micro Devices (AMD) and GW Pharmaceuticals PLC- (GWPH).

(COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.03%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan and Scott Dreyer. View institutional ownership trends for Collegium Pharmaceutical.

COLL stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. View insider buying and selling activity for Collegium Pharmaceutical.

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of COLL stock can currently be purchased for approximately $16.52.

Collegium Pharmaceutical has a market capitalization of $567.30 million and generates $296.70 million in revenue each year. The specialty pharmaceutical company earns $-22,720,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.

The official website for Collegium Pharmaceutical is www.collegiumpharma.com.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.